{"analyses":[{"ciLowerLimit":"0.56","ciPctValue":"95","ciUpperLimit":"0.85","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","paramType":"Hazard Ratio (HR)","paramValue":"0.69","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6"},{"groupId":"OG001","value":"22.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"702"}],"units":"Participants"}],"description":"Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \\>/=50% increase in any node \\> 1 centimeter (cm) or \\>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \\> 1.5 cm or \\>/= 50% increase in any previously involved node with a diameter \\</= 1 cm such that it is now \\>1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.","groups":[{"description":"Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline up to data cut-off (up to approximately 5 years and 2 months)","title":"Event-Free Survival (Overall Study Population)","type":"SECONDARY","unitOfMeasure":"percentage of participants with event"}